HOME >> MEDICINE >> NEWS
Predicting serious cardiac outcomes

Ischemia-modified albumin appears in the serum within minutes of ischemia, before myocete necrosis, and can be detected 6 hours or more after the onset of symptoms.

In this issue of CMAJ, Worster and colleagues describe how they evaluated the prognostic capabilities of high or low levels of ischemia-modified albumin in patients with potential cardiac-ischemia symptoms (within the preceding 6 hours) by recording outcomes such as death, myocardial infarction, heart failure, arrhythmia and refractory pain within 3 days of presentation. Their analysis, as underlined by Sabatine in a related commentary, showed that levels of ischemia-modified albumin provided no useful information in predicting which patients would have a serious cardiac outcome in the short term.


'"/>

Contact: Dr. Stephen Hill
hillstev@hhsc.ca
Canadian Medical Association Journal
20-Jun-2005


Page: 1

Related medicine news :

1. Predicting danger of flu pandemic rests on differences in affected population, says O.R. Forum
2. Predicting the quality of life for older adults
3. Predicting the risk of rheumatoid arthritis for early arthritis patients
4. Predicting an answer to the threat of flooding
5. Predicting outcomes for kidney transplant patients
6. Predicting successful outcomes in living-donor liver transplants
7. Predicting cardiovascular problems in liver transplant patients
8. Predicting the risk of death in patients with known coronary artery disease
9. Predicting the future of primary care in England
10. Predicting the outcome of drug-induced liver disease
11. Seat belt injuries could signal more serious trauma in children

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Predicting serious cardiac outcomes

(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: